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ABSTRACT - Purpose. Promoting and ensuring safe use of codeine containing medicines remains a public 
health issue given the rise in reporting of misuse and dependence particularly in countries where available over–
the-counter (OTC).  The aim of this unique study was to identify best practices in management of opioid abuse 
and dependence, particularly codeine, and innovations to meet challenges surrounding safe and compliant use, 
patient awareness-raising, reducing health harms and enhancing successful treatment of dependence.  
Methods. A mixed methods approach using three data points was used that included : (1) analysis of data from 
existing scoping reviews to identify potential areas for innovation  (2) interviews with key national stakeholders 
from public health, pharmaceutical, regulatory, primary care and addiction practice in three distinct regulatory 
regimes (Ireland, United Kingdom and South Africa); and (3) a circular email request for information on 
potential innovations to members of the European Medicine’s Agency European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCEPP). Data from these three sources were analysed to 
identify best practices and opportunities for innovation.  Results. Best practices and potential innovations were 
identified under the nine headings: (1) manufacture; (2) product information and public education; (3) 
responsible prescribing; (4) monitoring and surveillance; (5) dispensing,  screening and brief interventions in 
community pharmacies; (6) safety in the workplace and on the road; (7) internet supply of codeine and online 
support; (8) treatment of codeine dependence; and (9) learning resources and training for health professionals.  
Conclusions. Challenges ensuring availability of codeine containing medicines for legitimate therapeutic use, 
while minimising misuse, dependence and related health harms warrant consideration of new innovations. Most 
promising innovative potential lies across the products’ retail lifecycle from manufacture to prescriber and 
community pharmacy practitioner.   
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may 
comment by clicking on ABSTRACT on the issue’s contents page. 
  
 
BACKGROUND 
 
Codeine, or 3-methylmorphine, is the most 
commonly consumed opiate worldwide, widely 
used for its analgesic, anti-diarrhoeal and 
antitussive properties (1). Many countries restrict 
supply to prescription only, with over-the-counter 
(OTC) availability with differing regulatory policies 
on advertising, shelf visibility and direct pharmacist 
intervention at point of sale implemented in many 
countries including Australia, New Zealand, 
Canada, South Africa, France, Ireland and the 
United Kingdom (UK) (2-3). The rise in misuse of 
OTC codeine-containing products is of increasing 
concern and has stimulated calls for upscheduling, 
increased pharmaco-vigilance and development of 
innovative proactive public health, primary care and 
community pharmacy initiatives (3, 6-7). Misuse, 
when referring to use of medicines, is defined as 
‘the problematic consumption outside of acceptable 
medical practice or medical guidelines, when self- 
medicating at higher doses  and for longer than is  
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 advisable, for intoxicating purposes and when risks 
and adverse consequences outweigh the benefits’ 
(4). 
 Codeine has an identified abuse potential due 
to its opiate effect and development of tolerance 
within a short timeframe (8), and by reported 
patient dependence (9).  Neuro-adaptation occurs 
with repeated use (therapeutic and non-therapeutic) 
within a short period of time (10, 11). Prolonged 
use is strongly associated with depression and 
dysphoric mood states, and how codeine can 
interact with other substances leading to respiratory 
depression and other central nervous system effects 
(3,5).
. 
Of particular public health concern is that 
long term or excessive use of codeine combination 
products containing additives (ibuprofen and 
paracetamol/acetaminophen) can lead to chronic 
headache, gastrointestinal haemorrhage, 
inflammatory bowel conditions, hypokalaemia, 
acute haemorrhagic necrotising pancreatitis, and 
neurological damage  (3,5). The rise in patient 
uptake of addiction treatment services for this form 
of opioid analgesic dependence is equally 
concerning (12, 13).  
 Challenges for policy makers and 
practitioners centre on how to ensure availability of 
codeine containing medicines for legitimate 
therapeutic use, while minimising consumer risk of 
misuse, dependence and related health harms (6-7, 
14-15). This is complicated by the complexity of 
inter-relations between pharmacological, social, 
economic, legal and individual factors which shape 
consumption patterns; the heterogeneous nature of 
misuse; blurring between therapeutic use and 
misuse; focus of drug agencies on surveillance of 
opiate users and dependents; difficulties in 
estimating prevalence of misuse given the broad 
definition of misuse and the covert nature of 
medicinal misuse itself; and the presence of 
displacement between public sourcing of 
prescribed, OTC and internet sourced products (3, 
6, 14).  
 In September 2013 a 3-year, European Union 
funded, multi-country research project between 
academic and community pharmacy sectors was 
initiated in Ireland, the UK, and South Africa. This 
project called CODEMISUSED, aimed to 
investigate codeine use, misuse and dependence in 
partner countries.  A scoping review of the 
literature on codeine was conducted (5, 15) and this 
review was used to identify existing and specific 
best practice strategies to address codeine misuse 
and dependence centring on: product manufacture; 
product information and public education; 
responsible prescribing; monitoring and 
surveillance; dispensing, screening and brief 
interventions in community pharmacies; safety in 
the workplace and on the road; internet supply of 
codeine and technological support; treatment of 
codeine dependence; and training for health 
professionals. In this paper we build on these 
reviews (5, 15) by presenting the key identified best 
practices and potential innovations to meet 
challenges in management of codeine use, misuse 
and dependence.   
 For the purpose of our analysis we defined 
innovations as ‘a novel concept or a new way of 
doing things to reduce the risk of codeine misuse 
and dependence which has not yet become best 
practice.’  Distinguishing an innovation from best 
practice (which might once have been innovations, 
but are now widely implemented), involved 
professional judgement by the authors based upon 
evidence garnered in this study. Disagreements 
between the authors about whether an intervention 
or practice was an example of innovation or was 
best practice were resolved through discussion, with 
reference to the available evidence.   
 
METHODS 
 
A  mixed methods approach using three data points 
that included: (1) further analysis of data collected 
from the scoping reviews to identify areas for 
innovation (5,15); (2) interviews with key national  
stakeholders from public health, pharmaceutical, 
regulatory, primary care and addiction practice in 
three distinct regulatory regimes (Ireland, UK and 
South Africa); and (3) a circular email request for 
information on potential innovations to members of 
the European Medicine’s Agency European 
Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance (ENCEPP).  
 
Scoping Reviews of the Global Literature on 
Codeine Use, Misuse and Dependence (5,15) 
Databases searched included PubMed, EBSCO 
Host, Science Direct, EMBASE, PsycINFO, 
Cochrane library and Medline from 1994 to 2014. 
Search terms used were in English and included: 
‘codeine’; ‘dihydrocodeine’; ‘opiate medication’; 
‘opioid misuse/abuse/diversion/addiction’; ‘opioid 
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dependence’; ‘over the counter codeine/medicine’; 
‘analgesics’; ‘prescription opioids’; ‘self-
medication’; ‘pain’; ‘pharmacy’; ‘medical’; and 
‘treatment’. Follow up search strategies included 
hand searching, searching of pharmaceutical, 
health, medical, drug related websites, and 
contacting key organisations such as the World 
Health Organisation (WHO), International 
Narcotics board (INCB) European Medicines 
Agency (EMA), European Monitoring Centre for 
Drugs and Drug Abuse (EMCDDA), authorised 
medicine boards in each of the European membered 
states, the US Federal Drug Administration (FDA), 
the Canadian pharmacy authority, and the UK 
National Health Service (NHS). See Table 1 for 
inclusion and exclusion criteria.  
 Two reviewers independently screened titles 
and abstracts to identify articles reporting an 
innovation to reduce the risk of misuse of codeine 
or other over the counter medication with misuse 
potential. Disagreements were resolved by 
discussion with a third researcher. Reference lists of 
retrieved papers were hand searched for any 
additional relevant papers. 117 articles remained 
following application of exclusion criteria and 
removal of duplicates. See Figure 1.  
 
Interviews with National Stakeholders in 
Ireland, UK and South Africa 
Conversational interviews were conducted with a 
purposive sample of key informants based in 
Ireland (n=5), the UK (n=6) and South Africa (n=9) 
who were identified as having either a strategic role 
nationally or internationally in the development of 
codeine misuse and dependence services and/or 
experience of developing and implementing 
innovations across the codeine misuse or OTC 
medication field. The sample was identified through 
community pharmacy organisations in each 
country. Snowball sampling was used whereby each 
interviewee was asked to nominate other potential 
individuals at the forefront of innovations relating 
to codeine misuse and dependence.   
 The interview guide was informed by a 
scoping of the literature with regards to challenges 
and heterogeneities of codeine misuse, current best 
practices, and identified areas for innovative 
approaches – see for example the report   produced 
by the National Treatment Agency for Substance 
Misuse in the UK (16). Interviews were conducted 
either   face-to-face   or   by   telephone.    Interview  
Table 1: Study inclusion and exclusion criteria 
Inclusion criteria 
 Research studies of prevalence or incidence of 
prescribed and over the counter codeine use, 
misuse, abuse, diversion, treatment and 
dependence in adult populations. 
 Research studies that describe the tampering of 
codeine containing medicines. 
 Reports of interventions for the treatment of 
codeine dependence.  
 Reports of pharmacy based interventions for 
codeine use and misuse. 
 Research studies of at risk groups and other 
illicit drug users that use, misuse or are 
dependent on codeine.  
 Research studies which examine the 
effectiveness of codeine in pain management.  
 Research studies examining pharmacovigilance, 
pharmacodynamics and pharmacokinetics with 
particular reference to codeine. 
 Literature in relation to the sale, consumption 
and manufacture of codeine. 
 Policy documents on the scheduling of codeine 
medicine products. 
 Policy documents and guidelines with particular 
reference to codeine. 
Exclusion criteria 
 Anecdotal and opinion based literature about 
prescribed and over the counter codeine use, 
misuse, abuse, diversion, treatment and 
dependence in adult populations. 
 Literature not available in English. 
 Articles where full text was not available.  
 Empirical studies examining codeine in animal 
populations. 
 
 
duration ranged between 20 and 90 minutes and 
were audio recorded.  
 
Email Request for Information on Innovations 
to Members of the ENCEPP  
A circular email was sent by the ENCEPP network 
of the European Medicines Agency, London, UK to 
all European centres (n=139) requesting them to 
contact the CODEMISUSED Principal Investigator 
(author four) with information relating to 
innovations they were aware of for managing  
codeine misuse and dependence. Three responses 
were received.  
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Figure 1: Flow diagram of articles accessed 
through the scoping review 
 
 
 
 
Data Analysis  
Data was analysed collectively and summarised 
under nine headings: (1) manufacture; (2) product 
information and public education; (3) responsible 
prescribing; (4) monitoring and surveillance; 
(5) dispensing, screening and brief interventions in 
community pharmacies; (6) safety in the workplace 
and on the road; (7) internet supply of codeine and 
online support; (8) treatment of codeine 
dependence; and (9) learning resources and training 
for health professionals.  
 
RESULTS 
 
We present here the results in two sections, namely 
‘Best Practices’ and ‘Innovations’. 
 
Best Practices 
Manufacture 
Abuse deterrent formulations can prevent drug 
users extracting the active ingredient in order to 
consume greater amounts, or the home manufacture 
of deso-morphine for injecting purposes (17). 
Formulations can also be designed to deter 
reinforcing effects of opioids through the 
incorporation of antagonists or other ingredients 
that become active only when the analgesic is used 
improperly (18). 
 
Product Information and Public Education 
Measures such as increased visibility of warnings 
on labels and leaflets (i.e. ‘Can cause addiction. 
For 3 days use only’), (19) are features of the retail 
environment of community pharmacies in many 
European countries designed to deter codeine 
misuse and dependence. However, key informants 
pointed out that in their experience the public 
ignore such information.  
 
Responsible Prescribing 
Multidisciplinary assessments of opioid dependence 
are advocated that incorporate physical, 
psychological, social, and environmental factors. 
Monitoring strategies include patient reports of side 
effects and therapeutic effects, urine testing, pill 
counts, consulting prescription databases, 
interviews with family and caregivers and patient 
observations. Prescribers and other health providers 
are advised to assess and monitor risk by asking 
opioid patients about current, past and family 
history of addiction (20) and current/past levels of 
OTC use (21). Doctor questioning about over-
sedation, feeling intoxicated, requesting early 
refills, self-increasing dosage have also been 
identified as useful screening questions to predict 
patients at risk (22).  Savage (23) also includes 
amongst opioid aberrant behaviours: so called 
patient ‘drug allergies’ which limit treatment 
options; frequent late or missed appointments; 
patient history of no therapeutic response to any 
pharmacological treatment except opioids; requests 
for medications at the end of a consultation; 
negative description of prior interactions with 
prescribers; and presence of pain out of proportion 
to identified nociceptive process. Opioid 
agreements have also been used to establish a 
contract between prescribers and patients and have 
been used as grounds for discontinuation of opioid 
3105 articles identified through database 
searching  
 475 articles screened for inclusion criteria 
149 studies included in the final review 
and synthesis under main thematic 
headings   
Final number of articles charted  = 117  
Final screening and 
further removal of non-
specific articles  n=33 
22 other records 
included (reviews 
papers, reports etc 
242 full text articles 
retrieved  
233 abstract  identified 
and excluded for charting 
91 record excluded for lack 
of specificity to codeine  
475 total number after 
duplictes and non language 
english removed 
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prescribing.   
 
Monitoring and Surveillance 
Well-designed real-time reporting systems aim to 
track and monitor levels of dispensing of opioid 
containing medicines, reduce inappropriate 
prescribing, prescription shopping and unsanctioned 
use, prevent ‘pharmacy-hopping’ in the event of 
refusal of sale and reduce adverse events such as 
overdose. However, these systems typically do not 
include codeine and require extensive evaluation 
and process monitoring, with potential unintended 
consequences including: overly cautious prescribing 
of higher schedule opioids and a shift toward mid-
range scheduled opioids to avoid scrutiny; 
displacement of consumer behaviour to include 
alcohol, other prescription drugs and illicit drugs; 
increases in pharmacy and warehouse theft; and 
inconsistent responses by doctors to real-time 
reporting information (24-26).  
 
Dispensing, Screening and Brief Interventions in 
Community Pharmacies  
Regulatory responses to misuse of OTC codeine 
have to date included changes in pack sizes, 
maximum unit doses, maximum daily dose, 
warning labels, consumer medicine information, 
pharmacist intervention at point of sale, restriction 
of self-selection and advertising (27). Suspected 
misuse in pharmacies centres on customer repeated 
requests for certain codeine containing products by 
name; refusal to consider single ingredient products 
(i.e. paracetamol, aspirin or ibuprofen); requesting 
specific pack sizes; and agitation when pharmacists 
intervene. Pharmacy tactics currently include 
removal of codeine containing products displayed at 
point of sale, refusal of sale or restriction of the 
quantity sold in the event of suspect requests, on-
site recording of incidences of suspected misuse, 
medicines information provision by medicines 
counter assistants and pharmacists, direct 
pharmacist intervention by additional customer 
questioning, and customer referral to primary care 
professionals.  
 
Safety in the Workplace and on the Road 
Various workplace intervention programmes exist 
to train workers to recognise, intervene and refer 
co-workers with a substance abuse problem. 
Specific work place drug testing methods (urine and 
hair) are implemented in certain settings, with some 
countries implementing drug driving legislation 
(28). However, testing is hampered by cross-
sensitivity between illicit and prescription opioid 
drugs.  
 
Treatment of Codeine Dependence 
Buprenophine and methadone are presently used in 
substitution treatment. Cognitive behaviour therapy 
as adjunct has demonstrated efficacy as both a 
monotherapy and as part of combination treatment 
strategies to address opioid dependence (29).
 
These 
include helping the client to monitor internal and 
external cues for craving and manage the urge to 
take the substance through techniques such as self-
soothing, distraction techniques, physical exercise 
or staying with the craving without succumbing. 
Avoidance of blame, reinforcement of positive 
coping styles, reinforcing positive social supports 
and a robust relapse prevention plan are central to 
treatment approaches.  
 
Learning Resources and Training for Health 
Professionals 
Strategies to improve pharmacist counselling skills 
and enhance customer engagement in health care 
advice, screening and brief intervention processes 
have also been implemented in some settings. 
Education and training programmes advise health 
professionals to include detail on the patient 
characteristic of non-medical use of pharmaceutical 
opioids and dependence, risks and benefits of 
prescribed and OTC opioids, clinical care issues 
relating to identification of opioid aberrant 
behaviours, pain management, how to refuse opioid 
seeking behaviours, monitoring approaches and 
appropriate referral mechanisms for treatment (30). 
Comprehensive training programmes and 
coordinated inter-agency supports for doctors in the 
assessment, identification of potential misusing 
patients, and management of coexisting addiction 
and chronic non-malignant pain exist and include 
training in conflict resolution and techniques for 
declining patient demands (31). 
 
Innovations 
Forty five opportunities for innovation were 
identified in nine areas. Table 2. 
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Table 2: Listing of Innovations by Area 
 
 # Intervention 
Manufacture 1 Development of barriers to tampering and deterrent of misuse of combination codeine 
tablets by using binders in oral formulations, coating, bead or crush resistant 
compounds, time release matrixes, gel capsules 
2 Increase safety of combination codeine-paracetamol products through including an 
antidote to prevent paracetamol overdose 
3 Tamperproof preparations should be required and backed by legislation and drug 
companies provided with incentives to invest in these products 
4 Bar code individual tablets in a blister pack to allow the providence of tablets to be 
traced in cased where problems arise 
5 Manufacture smaller packs of codeine which would give only 3-days’ supply 
6 Colour coding of all dependence producing tablets 
7 Review the safety of all available opioids (including codeine) to identify a single opioid 
that has the maximum safety, to be used in all combination preparations sold over the 
counter 
Product 
Information 
& Public 
Education 
8 Parenting classes highlighting the potential side effects of codeine, relating to 
metabolism and harms such as respiratory depression and sedation 
9 Increase media coverage of the problem of codeine misuse and dependence 
10 Development of a logo to identify all dependence producing medications/preparations 
11 Increase the visibility of health warnings on the outside of packs of tablets containing 
codeine 
12 Increasing the visibility of the names of generic drugs included in combination 
medications, and related harms in excessive or long term use 
13 Public health campaigns that highlight that anyone can become addicted to codeine 
products when used long term or excessively 
14 Development of a protocol to guide health professionals how to approach screen  and 
advise members of the public to raise their awareness of the risks of codeine misuse and 
dependence   
Responsible 
Prescribing 
15 Cochrane review to evaluate the effectiveness of codeine for acute pain 
16 Promote an extensive opioid prescribing resource on all facets of prescribing both weak 
and strong opioids (including recommendation to assess psycho-social issues that might 
be precipitating or supporting the dependence) 
17 Abuse risk of codeine to be clearly indicated at time of prescription in the prescribing 
manuals and on prescribing decision computer software 
18 Handwritten prescription and the regular three monthly review of prescriptions to avoid 
repeat prescriptions which can occur almost by default 
19 All patients prescribed codeine products to be registered at a nominated community 
pharmacy 
20 Prescriptions for codeine preparations should be for a maximum of one week 
21 Prescribing of codeine to be confined to prescribers who are trained in addiction  
22 Discharge patients from pain clinics and hospital with non-opioid containing 
medications 
23 Development and testing of a gold standard patient risk assessment tool or procedure for 
codeine misuse and dependence 
 
Table 2 Cont'd 
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Table 2 Cont'd 
 
Monitoring 
& 
Surveillance 
24 National integrated prescriber and pharmacy monitoring of medicines using real time 
reporting analysis 
25 Monitoring prescribed and OTC codeine sales and purchases through shared patient 
records 
26 Purchases of OTC and prescribed medications recorded on the patients’ own data card 
27 Systematic monitoring to establish the prevalence of codeine dependence  
28 Periodic audits of codeine prescription and dispensing practices 
29 Adopt the methodologies implemented by the Codeine Care Initiative, South Africa -- 
which uses a 2D barcode printed on the packs of all codeine containing medicines to 
advise the customer and dispenser of amount of codeine purchased per month 
30 Develop secure central database to monitor the purchases of codeine nationally 
Dispensing, 
Screening & 
Brief 
Interventions 
in 
Community 
Pharmacies 
31 Pseudo-customer visits to audit pharmacist intervention at point of sale and performance 
feedback  
32 Health information posters in community pharmacies 
33 Require customers to sign on receipt of codeine preparation to indicate they are aware of 
its dependence potential 
34 Develop and validate  brief self-screening measure to identify pharmacy customers who 
misuse codeine 
35 Develop and test a brief intervention modelled on the Very Brief Advice on Smoking 
Intervention developed by the National Centre for Smoking Cessation and Training 
(NCSCT) 
36 Incorporate codeine related enquiry within pharmacists’ medication use reviews, and 
with enhanced communication between prescribers and pharmacists 
37 Strengthen the contribution of community pharmacists to treatment of codeine misuse 
and dependence through direct referral to primary and secondary care services; and 
delivery of community detoxification programmes in conjunction with the prescriber 
Safety in the 
Workplace 
& on the 
Road 
38 Integrating an employee assistance programme with drug testing to include opioids 
39 Compulsory urine testing for codeine in certain workplaces 
Internet 
Supply of 
Codeine & 
Online 
Support 
40 Use mobile phones as a medium for delivery of targeted patient health information and 
support interventions 
41 Regular audit of top ranked Google websites to check accuracy of health information on 
codeine use and misuse 
42 Health warnings as a pop-up feature of Internet shopping sites 
Treatment of 
Codeine 
Dependence 
43 Supplement the work of pain clinics by patient self-help courses, courses on pain 
management and self-help websites 
 Investment in m-Health: Further development and testing of mobile phone messaging to 
support adherence to treatment (part of innovation 40 above) 
44 Establish specialist codeine treatment clinics 
 Learning  
Resources & 
Training for 
Health 
Professionals 
45 Motivational interviewing (MI) training for all health professionals 
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Manufacture 
Some key informants believed that combination 
products (e.g. codeine with paracetamol) should not 
be manufactured because of risk of liver damage 
with prolonged use and that it would be safer to sell 
the drugs as separate items. Others were concerned 
that single codeine products would result in misuse 
and risk of tampering. It was further suggested that 
if these combination products continue to be 
manufactured, that all such preparations should 
contain an antidote (e.g. methionine sold with 
paracetamol). The technology is now also available 
to bar code tablets within a blister pack which 
would enable the supply of tablets containing 
codeine to be identified in cases of people who have 
taken an overdose and where empty packs are 
available. Since the warning on the pack or on 
information sheets in packs of codeine states that 
the medication should not be taken for more than 3-
days, it was also proposed that smaller packs at a 
high retail price be produced which contain only 3-
days’ supply. Key informants suggested 
development of a bright logo stamped on boxes of 
codeine products which indicates to consumers the 
risk of addiction. In addition tablets containing 
codeine could be manufactured in a specific colour 
(black or other unattractive colour).   
 
Product Information and Public Education 
The potential deterrent effect of having additional 
health warnings with greater visibility on the 
outside of codeine packages was suggested. 
Suggestions included; ‘This medicine contains 
codeine’ to more specific warnings such as, ‘Not to 
be taken by children, pregnant women or 
breastfeeding mothers’. Some remarked that 
although many countries now have advertising 
restrictions on codeine containing products, the 
trade names of some of these products are attractive 
to customers because they infer a superior product 
for example,  ‘Nurofen® Plus’. To counteract this, 
it was suggested that the trade name be given less 
prominence. Several remarked that a major 
challenge was attracting codeine misusers and 
individuals dependent on codeine into treatment 
because they do not identify themselves as addicts. 
This highlights the importance of public health 
campaigns which indicate that anyone can 
(inadvertently) become addicted to codeine.   
 
 
Responsible Prescribing 
It was suggested that emerging evidence states that 
codeine is of little value for chronic pain and that 
codeine preparations should become a prescription 
only medication (POM). However, there was not 
widespread consensus on this issue. A Cochrane 
Systematic review to investigate the efficacy of 
pain medicines available OTC in the UK for acute 
pain (32) should provide guidance on self-
medication for acute pain, as well as responsible 
prescribing decisions. In 2015, The British Pain 
Society and Medical Royal Colleges released an 
opioid prescribing resource (33) and this innovation 
is aimed at increasing knowledge about all facets of 
prescribing both weak and strong opioids. Several 
key informants recommended that a full assessment 
be undertaken by physicians managing chronic pain 
and that this should include a focus on the bio-
psycho-social issues that might precipitate or 
support dependence on codeine.   
 There was widespread agreement on the 
merits of the need to highlight abuse risk of codeine 
in prescribing manuals and in prescribing decision 
computer software.  Key informants also noted that 
prescriptions are often repeated automatically 
which can perpetuate codeine misuse as 
prescription renewals often pass unnoticed.  One 
suggestion was that prescribers should be required 
to hand write repeat prescriptions, rather than 
simply sign them off. All patients in receipt of 
prescribed codeine products should be required to 
register with a community pharmacy and that the 
prescription is sent to the nominated pharmacy by 
fax/email. This would enable a second check on 
repeat prescriptions by the pharmacist. Given the 
potential risk for codeine dependence within a short 
time frame, all prescriptions for codeine 
preparations should ideally be for a maximum of 
one-week.  One participant suggested that 
prescribers who are addiction specialists should 
only have prescribing authority to prescribe codeine 
containing medicines.  
 It was suggested that doctors and other health 
professionals rarely consider the possibility of 
overdose of other drugs within combination codeine 
preparations. Being alert to this possibility could 
avoid undetected problems and patient delays in 
seeking help for potentially serious conditions. The 
use of opioid agreements establish a written 
contract between prescriber and patients and 
highlight to patients the risks involved in taking 
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codeine. It was also noted that the origins of 
codeine dependence for a substantial proportion of 
people is on discharge from pain clinics and 
hospital. Thus, one suggestion was that patients 
discharged from pain clinics should be discharged 
on non-opioid containing pain medications. 
Furthermore, there is currently no widely accepted 
‘gold standard’ test for assessing opioid 
dependence and no risk tools for identification of 
codeine risk and dependence, and therefore, another 
innovation identified is to develop and test an 
instrument for screening in practice. Additionally, 
prescribers and pain and addiction specialists may 
benefit from further specialised training in assessing 
and managing coexisting addiction and chronic 
non-malignant pain. 
 
Monitoring and Surveillance 
Electronic patient records which are shared across 
prescribers and similar systems across community 
pharmacists, have the potential to provide real time 
reporting and to deter patterns of misuse through 
compulsory centralised recording of the name and 
address of persons that  codeine products are issued 
to. Identity cards can additionally act as deterrence 
for the purchase of OTC and POM, and could 
include a chip to produce a personal record of 
purchases of medicines with the potential for 
dependence, such as codeine. This could also be 
built into national health insurance cards where 
such cards exist. Production of the card at point of 
purchase of prescription would enable the 
community pharmacist, the GP or non-medical 
prescriber to check previous purchases of codeine 
or other dependence forming medication. An 
alternative would be for patients/customers to 
provide their social security/national insurance 
number.  
 While development and implementation of a 
real-time monitoring/reporting scheme using 
patients’ own identity cards (or similar) could raise 
civil liberties issues and also some technology 
barriers, several of our key informants thought it 
would be feasible. The distribution of codeine 
should be tracked and prescribing practices audited 
to identify outliers who dispense larger quantities of 
codeine preparations. Audits could also identify 
patients whose pain has not been reviewed, those 
who have been on repeat prescriptions for a long 
period as well as markers for potential drug misuse, 
such as frequently losing prescriptions. The 
Codeine Care Project launched in South Africa is an 
ambitious attempt at real-time monitoring of 
codeine OTC sales in community pharmacies. The 
initiative uses a barcode printed on the packs of all 
codeine containing medicines and a very secure 
central database to monitor the national purchase of 
these medicines.  
 
Dispensing, Screening and Brief Interventions in 
Community Pharmacies  
Community pharmacies were identified as a good 
setting for public health posters inviting people to 
approach the pharmacist if they, or someone they 
know, might have a problem with painkillers. 
Pharmacy customers who buy a codeine containing 
medicine should be required to sign that they have 
received such a product. Key informants also 
pointed to the difficulty of identifying people who 
may be misusing or dependent on codeine. It was 
further suggested that a self-screening leaflet could 
be given to all purchasers of codeine related 
products to identify those with a codeine misuse 
problem inviting them to speak to the pharmacist. 
 Key informants suggested that a measure 
similar to the Alcohol Use Disorders Identification 
Test (AUDIT) (34) the Drug Abuse Screening Test 
(DAST) (35) or the Very Brief Advice on Smoking 
Intervention (36) could be administered to all 
customers who purchase or are prescribed a codeine 
combination preparation. If the customer scores 
above a certain level the pharmacist would give 
him/her a phone number to ring or, with the 
customer’s agreement, make an appointment for 
them with a specialist practice nurse or other health 
professional. 
 Community pharmacists in some countries 
currently offer all customers a medication use 
review (MUR) and in the UK this is a free universal 
service. It was suggested that codeine use, and 
painkiller use more generally, should be 
incorporated into MURs as a matter of routine. Key 
informants highlighted how the direct referral of 
patients to general practitioners or secondary 
services would result in a more integrated service 
for misusers of OTC codeine containing medicines. 
A good relationship with the community pharmacist 
with intervention in the event of suspected problem 
use is seen as a trigger for help seeking behaviour. 
Key informants also spoke of the potential for 
community pharmacists to deliver structured detox 
treatment programmes for codeine misusers. 
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Safety in the Workplace and on the Road 
A policy of mandatory drug testing to include 
screening for OTC codeine in the workplace was 
identified as having the potential to identify 
potential misusers of codeine. However, we are 
aware that having a prescription for codeine may 
legitimate positive urine screening results, but may 
not necessarily highlight misuse or abuse of the 
drug. Mandatory drug testing in the workplace may 
not be acceptable in all settings; but building on the 
success of employee assistance programmes in the 
US, these could also be developed to include 
identification, assessment, support and referral of 
workers who are misusing OTC and prescribed 
codeine products. Police may also conduct drug 
tests on motorists they suspect of driving under the 
influence of codeine. However, there are technical 
problems in roadside testing because while the test 
used for morphine will pick up codeine, codeine 
can remain in the system for two days. 
 
Internet Supply of Codeine and Online Support 
Purchasing trends have diversified to include online 
pharmacies and this is likely to increase over time, 
but questions remain about consumer informed 
decision making of the risks of using online 
pharmacies. Key informants pointed to the need for 
doctors to question patients around their use of the 
Internet for medical information, particularly in the 
case of pain, and sourcing of medicines. Patient 
education in partnership with health professionals 
via medical web-links are a promising 
development. One innovation that was proposed to 
curb problems associated with the internet supply of 
codeine products was for a regulatory or other 
agency to conduct regular audits of top ranked 
Google websites to check accuracy of health 
information on codeine use and misuse. This could 
confirm that accurate health information about the 
risks of codeine appear high up on a Google search.  
It was further proposed that on-line shopping sites 
be asked to introduce a ‘health warning’ pop-up 
and e-health screening in response to searches to 
purchase codeine containing preparations.   
 Consumer health technologies which 
facilitate management of information in 
computerised systems can also strengthen personal 
healthcare management. Several informants 
believed that mobile phone technology has the 
potential to support patients in treatment through 
text messaging and help to integrate addiction 
treatment into primary care, by enhancing the 
referral and treatment processes.  A series of 
Cochrane reviews (37-38) highlight the potential of 
mobile phone messaging as a medium for 
delivering interventions to facilitate self-
management of long term illness and for preventive 
healthcare. Many respondents believed that M 
(mobile)-Health had great potential for use in 
tapering programmes for codeine dependence 
within integrated primary care and community 
pharmacy settings. Similarly the Internet offers the 
potential to engage with and support codeine 
dependents.   
 
Treatment of Codeine Dependence 
There is a need to develop standardised criteria to 
determine client codeine dependence as well as 
referral and treatment pathways for OTC codeine 
dependence. However, the main challenge centres 
on attracting codeine misusers into treatment, 
because they do not identify themselves as addicts 
or believe they have the susceptibility to become an 
addict. Specific services could be developed for 
codeine addiction, along with public health 
campaigns which highlight that anyone can become 
addicted to codeine. One informant specifically 
raised the need for specialist residential 
detoxification facilities for codeine dependence 
with existing treatment centres.  In addition to 
opiate agonist treatment modalities, key informants 
commented on the importance of psychosocial 
adjustment to prevent relapse following successful 
physical treatments for codeine withdrawal. Amato 
et al’s Cochrane review (39) included five 
psychosocial treatments (three forms of structured 
counselling, behaviour therapy and family therapy) 
which can potentially be used in adjunct therapy for 
codeine dependence. These were found to have a 
positive impact compared to pharmacological 
treatments alone, particularly in increasing 
abstinence from opiates at follow up. Other more 
novel psychological therapies have also been 
proposed as having an important role to play, for 
example, a Mindfulness Oriented Recovery 
Programme (40) was able to reduce patients’ 
cravings for opioid drugs and could be considered 
as part of a holistic treatment for codeine 
dependence.  
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Learning Resources and Training for Health 
Professionals 
The importance of trainee community pharmacists 
and other health professionals having high 
standards of supervised patient experience and 
dedicated addiction training as part of their 
education was highlighted. This could occur 
through co-location of academic departments in 
practice settings to minimise the theory-practice gap 
and maximise opportunities for trainees to apply 
theory to practice situations and improve their 
patient interaction skills. Motivational interviewing 
is now well established as an evidence-based 
patient-centred, semi-directive method for 
enhancing intrinsic motivation to change by 
exploring and resolving ambivalence. A Cochrane 
review of the effectiveness of motivational 
interviewing for substance abuse also provides 
some evidence to support this intervention with this 
distinct group of users (41). 
 
DISCUSSION 
 
To our knowledge, this is a first attempt to go 
beyond identified best practices in addressing and 
managing the challenges encountered by codeine 
use, misuse and dependence, and to identify 
innovations that can potentially reduce the risk of 
codeine misuse and dependence.  The innovations 
identified are likely to vary in relation to their 
potential endorsement by regulatory authorities, 
pharmaceutical manufacturers, health and 
community pharmacy practitioners, general public, 
and the degree to which they might restrict the 
availability of codeine for therapeutic use. In some 
instances these best practices are in place for 
stronger opioids, and warrant consideration for 
codeine. Given the challenges in ensuring 
availability of codeine containing medicines for 
legitimate therapeutic use, whilst minimising 
misuse, dependence and related health harms these 
innovations do warrant further consideration and 
inclusion in current regulatory and policy debate. 
Limitations in our approach centre on this first 
attempt in simply identifying routes for innovation. 
We recommend further research using Delphi 
strategies to underpin expert opinion globally in 
terms of impact and challenges to implementation.  
 To date, attempts to address codeine misuse 
and dependence have primarily centred on practices 
that relate to manufacturing, responsible 
prescribing, dispensing, monitoring and 
surveillance, education and psychosocial 
interventions  (3,6,7). While such practices, for 
example, ‘real time monitoring’ (The Codeine Care 
Project) are an important deterrent for misuse and 
dependence (7, 42-43), they are not solely 
sufficient. Recent data suggests that individuals 
who continue to misuse or are dependent on 
codeine containing medicines intentionally bypass 
‘real time monitoring’ practices and engage 
communication strategies centred on manipulation 
and deceitfulness either when negotiating scripts 
from their doctor or purchasing their medicines. 
Managing such behaviours require further advanced 
communications training for medical and pharmacy 
practitioners, particularly in the area of 
interpersonal communication strategies with a 
specific focus on motivational interviewing and 
brief interventions (44, 45).  
 Internet supply of medicines, including 
codeine containing medicines without prescription 
is a major societal issue (46, 47) with greater access 
to online information and improved product 
awareness required. Online interventions targeting 
alcohol use have shown promising results (48) with 
Web based social norms interventions also 
demonstrating effectiveness in reducing alcohol use 
and promoting smoking cessation (49). Codeine 
specific services and low threshold substitution 
treatments and support (51-52) coupled with 
innovative mechanisms in E & M -Health in 
treatment and recovery supports for individuals 
dependent on codeine has potential (53). For 
instance, the use of mobile phones as a medium for 
delivery of targeted patient health information and 
support interventions (38), regular audits of top 
ranked Google websites to check accuracy of health 
information on codeine use and misuse and health 
warnings as a pop-up feature of Internet shopping 
sites are potential areas for innovation.  
 There are mixed views with regards the 
merits or otherwise of retaining codeine in OTC 
available preparations (6). Jurisdictions with OTC 
availability of codeine containing products should 
consider all best practices and innovations prior to 
up-scheduling.  POM availability is not without its 
problems in terms of both over-prescribing and 
reducing access to a wide range of people who 
legitimately use codeine in favour of a minority 
who are codeine/opioid dependent (5, 54, 55). 
These issues require responsible and meaningful 
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consideration by all stakeholders. In terms of the 
more problematic drug users, pharmaceutical drug 
formulation technologies are continuously 
developing in order to create disincentives to reduce 
the incidence of product tampering and abuse (56-
60). For example, physical and chemical barrier 
approaches for developing abuse-deterrent drugs 
can reduce risk of tampering with opioids (56). 
Potential development and manufacturing of abuse-
deterrent formulations and novel product designs 
with regards to codeine containing medicines is 
recommended, particularly with regards to illicit 
and prescription opioid dependents abusing codeine 
containing medicines. Abuse deterrent approaches 
may deter cold water extraction of codeine from 
combination products. However, given that the 
majority of individuals who misuse and are 
dependent on codeine containing medicines 
originate from those with legitimate therapeutic 
need, efforts should focus more on the monitoring 
of compliance, patient awareness raising, 
management of iatrogenic dependence and support 
in the event of problematic use arising. Codeine 
misusers and those dependent do require intensive 
psycho-social interventions to support opiate 
agonist treatment, and do warrant consideration as a 
distinct patient group [51]. 
 
CONCLUSION 
 
Codeine misuse and dependence remains a public 
health issue and is widely debated at both policy 
and clinical levels.  This paper contributes to such 
debates around availability, compliance and 
reduction of harm, and offers policymakers and 
practitioners’ potential innovative ways forward. 
The challenge of ensuring continued availability of 
codeine containing medicines for legitimate 
therapeutic use whilst preventing misuse and related 
health harms warrants significant consideration. 
Most promising innovative potential lies across the 
products’ retail lifecycle from manufacture to 
prescriber and community pharmacy practitioner.  
While many specific innovations are identified, 
further expert consensus building approaches, and 
research on the applied nature of such innovative 
practices is required. 
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